CDT Equity Inc.
CDTHealthcareNASDAQBiotechnology · Last scanned Oct 22, 2026
Scan Results
Daily timeframeCDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. Valued at $163K, CDT is a micro-cap name in its sector. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Market Cap
$162,717
Beta
1.56
P/E (TTM)
0.00
P/E (Fwd)
—
EPS (TTM)
$46679.71
EPS (Fwd)
—
ROE
-69.7%
ROA
-23.4%
Cash
$747,000
Total Debt
$1.2M
Free CF
$19.6M
52W Change
-100.0%
Annual Financials
Cash vs Debt
Where CDT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CDT finished 99.96% below its 150-day moving average ($432.47) and 99.99% below its 200-day moving average ($1955.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CDT overbought or oversold?
At the October 20, 2026 close, CDT's RSI(14) was 2.8, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, CDT has $747K in cash with $1.2M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $19.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -69.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.56 means CDT is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. No single metric tells the full story. Reviewing CDT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.